Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study ; volume:21 ; number:1 ; day:13 ; month:4 ; year:2021 ; pages:1-11 ; date:12.2021
BMC cancer ; 21, Heft 1 (13.4.2021), 1-11, 12.2021
- Creator
-
Lin, Huanyi
Liu, Qilong
Zeng, Xianshang
Yu, Weiguang
Xu, Guixing
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-08156-1
- URN
-
urn:nbn:de:101:1-2021060220445999623007
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lin, Huanyi
- Liu, Qilong
- Zeng, Xianshang
- Yu, Weiguang
- Xu, Guixing
- SpringerLink (Online service)
Other Objects (12)
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer